Latest news

• Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

  Novartis has announced positive topline results from a phase 3 trial in which its investigational oral monotherapy iptacopan demonstrated 'clinically meaningful superiority' over anti-C5 therapies (eculizumab or ravulizumab) in adults ... Iptacopan acts

• Novartis’ iptacopan scores positive results in rare blood disorder PNH

  New treatment options are needed, and these positive results further strengthen the profile of iptacopan as a promising oral monotherapy. ... At the highest dose of 200mg twice daily, a 23% reduction in proteinuria was predicted with iptacopan treatment

• Novartis receives FDA breakthrough therapy designation for rare disease med

  Swiss pharma company Novartis has received a breakthrough therapy designation (BTD) for its experimental medication iptacopan for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). ... Iptacopan is the most advanced asset in our